Last updated on September 2017

Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients


Brief description of study

The purpose of this study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell transplant recipients.

Clinical Study Identifier: NCT02927067

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

John Baddley, MD, MSPH

University of Alabama at Birmingham
Birmingham, AL United States
  Connect »

Drew Winston, MD

UCLA Medical Center
Los Angeles, CA United States
  Connect »

George Lyon, MD

Emory University
Atlanta, GA United States
  Connect »

Kathleen Mullane, DO, PharmD

University of Chicago
Chicago, IL United States
  Connect »

Robin Avery, MD

Johns Hopkins Hospital
Baltimore, MD United States
  Connect »

Francisco Marty, MD

Brigham and Women's Hospital/Beth Israel Deaconess Medical Center
Boston, MA United States
  Connect »

George Alangaden, MD

Henry Ford Health System
Detroit, MI United States
  Connect »

Raymund Razonable, MD

Mayo Clinic
Rochester, MN United States
  Connect »

Genovefa Papanicolaou, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Ran Reshef, MD, MSc

Columbia University Medical Center
New York, NY United States
  Connect »

Emily Blumberg, MD

University of Pennsylvania
Philadelphia, PA United States
  Connect »

Aloysius Ho, MD

Singapore General Hospital
Singapore, Singapore
  Connect »

Gunhan Gurman

Ankara University
Ankara, Turkey
  Connect »